share_log

We Think Dalian BIO-CHEM (SHSE:603360) Might Have The DNA Of A Multi-Bagger

We Think Dalian BIO-CHEM (SHSE:603360) Might Have The DNA Of A Multi-Bagger

我們認爲大連生物化學(SHSE: 603360)可能擁有多袋機的DNA
Simply Wall St ·  05/21 12:35

What trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly, we'll want to see a proven return on capital employed (ROCE) that is increasing, and secondly, an expanding base of capital employed. Ultimately, this demonstrates that it's a business that is reinvesting profits at increasing rates of return. So when we looked at the ROCE trend of Dalian BIO-CHEM (SHSE:603360) we really liked what we saw.

我們應該尋找哪些趨勢?我們想確定可以長期價值成倍增長的股票?首先,我們希望看到經過驗證的 返回 關於正在增加的資本使用率(ROCE),其次是擴大 基礎 所用資本的比例。歸根結底,這表明這是一家以更高的回報率對利潤進行再投資的企業。因此,當我們查看大連生物化學(SHSE: 603360)的投資回報率趨勢時,我們真的很喜歡我們所看到的。

What Is Return On Capital Employed (ROCE)?

什麼是資本使用回報率(ROCE)?

For those that aren't sure what ROCE is, it measures the amount of pre-tax profits a company can generate from the capital employed in its business. To calculate this metric for Dalian BIO-CHEM, this is the formula:

對於那些不確定ROCE是什麼的人,它衡量的是公司從其業務中使用的資本中可以產生的稅前利潤金額。要計算大連生物化學的這個指標,公式如下:

Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)

已動用資本回報率 = 息稅前收益 (EBIT) ¥(總資產-流動負債)

0.22 = CN¥395m ÷ (CN¥2.1b - CN¥321m) (Based on the trailing twelve months to March 2024).

0.22 = 3.95億元人民幣 ÷(21億元人民幣-3.21億元人民幣) (基於截至2024年3月的過去十二個月)

So, Dalian BIO-CHEM has an ROCE of 22%. That's a fantastic return and not only that, it outpaces the average of 5.5% earned by companies in a similar industry.

因此,大連百凱的投資回報率爲22%。這是一個了不起的回報,不僅如此,它還超過了類似行業公司的平均5.5%。

roce
SHSE:603360 Return on Capital Employed May 21st 2024
SHSE: 603360 2024 年 5 月 21 日動用資本回報率

In the above chart we have measured Dalian BIO-CHEM's prior ROCE against its prior performance, but the future is arguably more important. If you'd like to see what analysts are forecasting going forward, you should check out our free analyst report for Dalian BIO-CHEM .

在上圖中,我們將大連百化先前的投資回報率與之前的表現進行了對比,但可以說,未來更爲重要。如果你想了解分析師對未來的預測,你應該查看我們爲大連生物化學提供的免費分析師報告。

What Can We Tell From Dalian BIO-CHEM's ROCE Trend?

我們可以從大連百凱的投資回報率趨勢中得出什麼?

Investors would be pleased with what's happening at Dalian BIO-CHEM. Over the last five years, returns on capital employed have risen substantially to 22%. The company is effectively making more money per dollar of capital used, and it's worth noting that the amount of capital has increased too, by 101%. So we're very much inspired by what we're seeing at Dalian BIO-CHEM thanks to its ability to profitably reinvest capital.

投資者會對大連生物化學發生的事情感到滿意。在過去五年中,已動用資本回報率大幅上升至22%。實際上,該公司每使用1美元資本就能賺更多的錢,值得注意的是,資本金額也增加了101%。因此,我們在大連生物化學所看到的情況給我們帶來了極大的啓發,這要歸功於它能夠盈利地進行資本再投資。

The Key Takeaway

關鍵要點

All in all, it's terrific to see that Dalian BIO-CHEM is reaping the rewards from prior investments and is growing its capital base. And with a respectable 42% awarded to those who held the stock over the last five years, you could argue that these developments are starting to get the attention they deserve. So given the stock has proven it has promising trends, it's worth researching the company further to see if these trends are likely to persist.

總而言之,看到大連生物化學從先前的投資中獲得回報並不斷擴大其資本基礎真是太棒了。而且,在過去五年中持有該股票的人將獲得可觀的42%的獎勵,你可以說這些發展已開始得到應有的關注。因此,鑑於該股已證明其趨勢令人鼓舞,值得進一步研究該公司,看看這些趨勢是否可能持續下去。

Like most companies, Dalian BIO-CHEM does come with some risks, and we've found 1 warning sign that you should be aware of.

像大多數公司一樣,大連生物化工確實存在一些風險,我們發現了一個你應該注意的警告信號。

If you want to search for more stocks that have been earning high returns, check out this free list of stocks with solid balance sheets that are also earning high returns on equity.

如果你想搜索更多獲得高回報的股票,可以查看這份資產負債表穩健且淨資產回報率也很高的股票的免費清單。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論